RISS 학술연구정보서비스

검색

인기 검색어

    다국어 입력

    http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

    변환된 중국어를 복사하여 사용하시면 됩니다.

    예시)
    • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
    • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
    닫기
    KCI등재 SCOPUS

    Interest of luspatercept in treatment of anemia in lower-risk of myelodysplastic syndrome anemia: a single center study of 26 patients

    한글로보기

    https://www.riss.kr/link?id=A110524243

    • 0

      상세조회
    • 0

      다운로드
    서지정보 열기
    • 내보내기
    • 내책장담기
    • 공유하기
      • URL 복사
    • 오류접수
    인용문이 복사되었습니다.

    부가정보

    다국어 초록 (Multilingual Abstract) kakao i 다국어 번역

    Background Myelodysplastic syndromes (MDS) are heterogeneous clonal hematological disorders characterized by ineffective hematopoiesis resulting in peripheral cytopenias. Luspatercept, an erythroid maturation agent, represents a novel therapeutic option for the management of anemia associated with low-risk MDS, particularly in patients with ring sideroblasts and/or SF3B1 mutations.
    Methods We retrospectively studied 26 adults with low- or intermediate-risk MDS who were treated with luspatercept from 2021 to 2024 at the Nice University Hospital. Data were collected from ORBIS and CLINICOM and analyzed using Microsoft Excel. Treatment was initiated at 1 mg/kg, depending on the patient.
    Results The median age was 74 years, and 38.5% of patients had the SF3B1 mutation. Erythroid response was achieved in 53.8% of patients according to International Working Group (IWG) 2023. Treatment was generally well tolerated, with fatigue being the most common side effect (26.9%).
    Conclusion Luspatercept appears to be effective in improving red blood cell production and reducing transfusion requirements in low-risk patients with MDS, with a favorable safety profile.
    번역하기

    Background Myelodysplastic syndromes (MDS) are heterogeneous clonal hematological disorders characterized by ineffective hematopoiesis resulting in peripheral cytopenias. Luspatercept, an erythroid maturation agent, represents a novel therapeutic opti...

    Background Myelodysplastic syndromes (MDS) are heterogeneous clonal hematological disorders characterized by ineffective hematopoiesis resulting in peripheral cytopenias. Luspatercept, an erythroid maturation agent, represents a novel therapeutic option for the management of anemia associated with low-risk MDS, particularly in patients with ring sideroblasts and/or SF3B1 mutations.
    Methods We retrospectively studied 26 adults with low- or intermediate-risk MDS who were treated with luspatercept from 2021 to 2024 at the Nice University Hospital. Data were collected from ORBIS and CLINICOM and analyzed using Microsoft Excel. Treatment was initiated at 1 mg/kg, depending on the patient.
    Results The median age was 74 years, and 38.5% of patients had the SF3B1 mutation. Erythroid response was achieved in 53.8% of patients according to International Working Group (IWG) 2023. Treatment was generally well tolerated, with fatigue being the most common side effect (26.9%).
    Conclusion Luspatercept appears to be effective in improving red blood cell production and reducing transfusion requirements in low-risk patients with MDS, with a favorable safety profile.

    더보기

    분석정보

    View

    상세정보조회

    0

    Usage

    원문다운로드

    0

    대출신청

    0

    복사신청

    0

    EDDS신청

    0

    동일 주제 내 활용도 TOP

    더보기

    주제

    연도별 연구동향

    연도별 활용동향

    연관논문

    연구자 네트워크맵

    공동연구자 (7)

    유사연구자 (20) 활용도상위20명

    해외이동버튼